We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Researchers Quantify the Uptake and Distribution of Targeted Nanoparticles

By LabMedica International staff writers
Posted on 23 Dec 2009
Nanoparticles linked to targeting molecules are increasingly being cited as potential chemotherapeutic agents, and a recent publication has now quantified how such molecules are distributed to various organelles within a target cell.

Investigators at Purdue University (West Lafayette, IN, USA) worked with nanorods constructed of gold and a magnetic material and coated with trastuzumab, an anticancer drug used to used to treat breast cancer that has metastasized in women whose tumor cells produce an overabundance of human epidermal growth factor receptor 2 (HER2). More...
The location of the nanorods in cultured breast cancer cells was determined by a combination of magnetic resonance spectrometry and microscopy. In some experiments, the drug was marked with a fluorescent molecule, and localization was quantified and diffusion times evaluated in different cell organelles by using fluorescence correlation spectroscopy (FCS).

Results published in the November 5, 2009, online edition of the journal ACS Nano revealed that, that in treated breast cancer cells the conjugated nanoparticles co-localized with the endosome and lysosome but not with the Golgi apparatus. The nanorods had similar intracellular localization characteristics as the fluorescently labeled drug. These findings not only lay the foundations for a quantitative understanding of the fate of nanoparticle-based targeting but also provide new insights into the rational design of nanoparticle delivery systems for effective treatment.

"Each nanoparticle acts like a deliverer of a mail package, or dose, of the drug directly to the appropriate location," said senior author Dr. Joseph Irudayaraj, professor of biological engineering at Purdue University. "We have demonstrated the ability to track these nanoparticles in different cellular compartments of live cells and show where they collect quantitatively. Our methods will allow us to calculate the quantities of a drug needed to treat a cancer cell because now we know how these nanoparticles are being distributed to different parts of the cell."

Related Links:
Purdue University



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.